Tradestie Institutional Equity Comparison Engine
ADRX vs ELAB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ELAB Overall Edge
ELAB Captures Institutional Edge (1โ1 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to PMGC Holdings Inc. Common Stock (ELAB) driven by superior Growth & Margin while ADRX counters with relative strength in Momentum & Technical. Fundamentally, ADRX trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ELAB at N/M Forward P/E and -470.0% operating margin (-45.8% YoY). In options structure, ADRX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ELAB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ADRX N/M vs ELAB N/M Fwd P/E
Growth & Margin Winner
ELAB
Op Margin N/A vs -470.0% ยท YoY N/A vs -45.8%
Momentum & Technical Winner
ADRX
1Y -27.6% vs -69.9% ยท 52W Pos 14% vs 8%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
ADRX
US Equity
ADRX
Institutional Equity
$14.00
-1.41% 1D
Market Cap
N/A
1M Return
-20.68%
1Y Return
-27.65%
Forward P/E
N/M
Unified AI Score
47.9 / 100
HOLD
Tech 50.0
Fund 50.0
Flow 50.0
Mom 50.0
ELAB
NASDAQ
PMGC Holdings Inc. Common Stock
Pharmaceutical Preparations
$1.66
+5.06% 1D
Market Cap
$1.3M
1M Return
-40.07%
1Y Return
-69.87%
Forward P/E
N/M
Unified AI Score
53.0 / 100
HOLD
Tech 60.0
Fund 50.0
Flow 50.0
Mom 55.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ADRX -27.65%
ELAB -69.87%
Spread: +36.03 pp (ADRX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ADRX TTM Op. Margin: N/A
ELAB TTM Op. Margin: -470.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADRX vs ELAB. Trailing 12-month operating profitability (ADRX N/A vs ELAB -470.0%) and valuation multiples (ADRX N/M vs ELAB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ADRX | ELAB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $1.3M | Larger Scale | ELAB |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | -45.8% | Higher Growth | ELAB |
| Operating Margin (TTM) Profitability | N/A | -470.0% | Higher Margin | ELAB |
| Net Profit Margin Profitability | N/A | 0.0% | Higher Margin | ELAB |
| Return on Equity (ROE) Capital Efficiency | N/A | -105.2% | Higher ROE | ELAB |
| 52-Week Range Position Momentum | 14% ($12โ$23) | 8% ($1โ$14) | Stronger Trend | ADRX |
| Beta / 30D Volatility Risk Regime | 1.05ฮฒ ยท 76% Vol | 5.47ฮฒ ยท 94% Vol | Lower Realized Risk | ADRX |
| Unified Institutional Score Composite Signal | 47.9 / 100 (HOLD) | 53.0 / 100 (HOLD) | Higher Composite | ELAB |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ADRX vs ELAB Buy Guide
ADRX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ELAB
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ADRX nor ELAB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.